AR088630A1 - Inhibidores del virus de la hepatitis c - Google Patents
Inhibidores del virus de la hepatitis cInfo
- Publication number
- AR088630A1 AR088630A1 ARP120104114A ARP120104114A AR088630A1 AR 088630 A1 AR088630 A1 AR 088630A1 AR P120104114 A ARP120104114 A AR P120104114A AR P120104114 A ARP120104114 A AR P120104114A AR 088630 A1 AR088630 A1 AR 088630A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- hydrogen
- orh
- heterocycle
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 23
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract 14
- 239000001257 hydrogen Substances 0.000 abstract 14
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910003827 NRaRb Inorganic materials 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- -1 -SRe Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), donde R¹ se selecciona entre alquilo C₁₋₆, alcoxi C₁₋₆, fenilo, cicloalquilo C₃₋₆, heterociclo, y heteroarilo, donde alquilo C₁₋₆ está opcionalmente sustituido con -ORᵃ, amino, -SRᵉ, heterociclo, o heteroarilo, alcoxi C₁₋₆ está opcionalmente sustituido con -ORᵃ, y heterociclo está opcionalmente sustituido con -ORᵃ, amino, o -C(O)O-alquilo C₁₋₆, o con uno o dos alquilo C₁₋₃ o =O; R² se selecciona entre hidrógeno y alquilo C₁₋₆; R³ se selecciona entre hidrógeno, alquilo C₁₋₆, -C(O)O-alquilo C₁₋₆, -C(O)NRᵐRⁿ, -C(O)cicloalquilo C₃₋₆, y -S(O)₂alquilo C₁₋₃; o R² y R³ junto con el átomo de nitrógeno al cual están unidos forman un heterociclo; R⁴ se selecciona entre alquilo C₁₋₆, -NRᵇRᶜ, -ORᵈ, -SRᵉ, -S(O)alquilo C₁₋₃, -S(O)₂alquilo C₁₋₃, -CN, C(O)NRᵃRᵇ, heterociclo, heteroarilo, y halo, donde alquilo C₁₋₆ está opcionalmente sustituido con -ORᵃ; y R⁵ y R⁶ son hidrógeno; o R⁴ y R⁵ son en forma independiente alquilo C₁₋₆ o halo y R⁶ es hidrógeno; o R⁴ y R⁵ tomados juntos forman -(CH₂)ₙ-, donde n es 2, 3, 4, ó 5; y R⁶ es hidrógeno; o R⁴ y R⁵ tomados juntos forman -O-(CH₂)₂-O- y R⁶ es hidrógeno; o R⁴ es hidrógeno y R⁵ y R⁶ tomados juntos forman -(CH₂)ₘ-, donde m es 1, 2, 3, ó 4; o R⁴ y R⁵ son cada uno hidrógeno y R⁶ es alquilo C₁₋₆; R⁷ se selecciona entre halo, alquilo C₁₋₃, y alcoxi C₁₋₃ donde alquilo C₁₋₃ y alcoxi C₁₋₃ están opcionalmente sustituidos con uno, dos, tres, cuatro, o cinco halo; R⁸ es alquilo C₁₋₃, opcionalmente sustituido con -ORʰ; R⁹ se selecciona entre alquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, -NRᶠRᵍ, heteroarilo, heterociclo, y -CH₂-heteroarilo; donde: alquilo C₁₋₆ está opcionalmente sustituido con uno o dos sustituyentes seleccionados en forma independiente entre -ORʰ, -NRʲRᵏ, -NHC(O)alquilo C₁₋₃, -NHC(O)O-alquilo C₁₋₃, -NHC(O)cicloalquilo C₃₋₆, cicloalquilo C₃₋₆, halo, -NHC(O)alquilo C₁₋₃(O)ORʰ, -NHC(O)alquilo C₁₋₃Rʰ, -NHC(O)NH-alquilo C₁₋₃, -NHS(O)₂alquilo C₁₋₃, y heterociclo; alcoxi C₁₋₆ está opcionalmente sustituido con -ORʰ; cualquier cicloalquilo C₃₋₆ está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados en forma independiente entre alquilo C₁₋₃, halo, NRᵃRᵇ, -ORʰ, y -CD₃, donde cualquier alquilo C₁₋₃ está opcionalmente sustituido con uno, dos o tres halo; cualquier heterociclo está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados en forma independiente entre alquilo C₁₋₃, halo, -C(O)O-alquilo C₁₋₃, -C(O)alquilo C₁₋₆, -C(O)cicloalquilo C₃₋₆, -C(O)NH-alquilo C₁₋₆, -C(O)NH-cicloalquilo C₃₋₆, -S(O)₂alquilo C₁₋₆, y -C(O)NH₂; donde cualquier -C(O)alquilo C₁₋₆ está opcionalmente sustituido con -NHC(O)O-alquilo C₁₋₃, -ORʰ, -NRʲRᵏ, o heterociclo, cualquier -C(O)cicloalquilo C₃₋₆ está opcionalmente sustituido con uno o dos alquilo C₁₋₃, y cualquier -C(O)NH-alquilo C₁₋₆ está opcionalmente sustituido con -ORʰ o cicloalquilo C₃₋₆; cualquier heteroarilo está opcionalmente sustituido con uno o dos alquilo C₁₋₃; Rᵃ, Rᵇ, Rᵉ, Rʰ, Rʲ, Rᵏ, Rᵐ, y Rⁿ son en forma independiente entre sí hidrógeno o alquilo C₁₋₃; Rᶜ es hidrógeno o alquilo C₁₋₆, donde alquilo C₁₋₆ está opcionalmente sustituido con -ORᵃ o amino; Rᵈ es hidrógeno o alquilo C₁₋₆, donde alquilo C₁₋₆ está opcionalmente sustituido con -ORʰ o con heteroarilo opcionalmente sustituido con alquilo C₁₋₃; Rᶠ es hidrógeno o alquilo C₁₋₆, donde alquilo C₁₋₆ está opcionalmente sustituido con -ORʰ; Rᵍ se selecciona entre hidrógeno, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆, NRᵃRᵇ, y heterociclo, donde alquilo C₁₋₆ está opcionalmente sustituido con -ORʰ y heterociclo está opcionalmente sustituido con uno o dos =O; R¹⁰ se selecciona entre hidrógeno, halo, y alquilo C₁₋₃, donde alquilo C₁₋₃ está opcionalmente sustituido con uno, dos o tres halo, o con -ORʰ; Aₘ es -NHC(O)- ó -C(O)NH-; a es 0, 1 ó 2; y b es 0, 1 ó 2; o una sal o estereoisómero farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555056P | 2011-11-03 | 2011-11-03 | |
| US201261600089P | 2012-02-17 | 2012-02-17 | |
| US201261637961P | 2012-04-25 | 2012-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088630A1 true AR088630A1 (es) | 2014-06-25 |
Family
ID=47146777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104114A AR088630A1 (es) | 2011-11-03 | 2012-11-02 | Inhibidores del virus de la hepatitis c |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9212168B2 (es) |
| EP (1) | EP2773634B1 (es) |
| JP (2) | JP6082747B2 (es) |
| KR (1) | KR20140091036A (es) |
| CN (1) | CN103946220B (es) |
| AR (1) | AR088630A1 (es) |
| AU (1) | AU2012332358B2 (es) |
| BR (1) | BR112014010401A8 (es) |
| CA (1) | CA2852700A1 (es) |
| CL (1) | CL2014001110A1 (es) |
| CO (1) | CO6940424A2 (es) |
| HK (1) | HK1200812A1 (es) |
| IL (1) | IL232042A (es) |
| MX (1) | MX347692B (es) |
| RU (1) | RU2625787C2 (es) |
| SG (1) | SG11201401891RA (es) |
| TW (1) | TWI577672B (es) |
| WO (1) | WO2013067267A1 (es) |
| ZA (1) | ZA201403198B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103189371B (zh) | 2010-11-04 | 2015-04-01 | 施万生物制药研发Ip有限责任公司 | 丙型肝炎病毒抑制剂 |
| CN104302636B (zh) | 2012-04-25 | 2017-03-29 | 施万生物制药研发Ip有限责任公司 | C型肝炎病毒抑制剂 |
| SG11201406552UA (en) | 2012-04-25 | 2014-11-27 | Takeda Pharmaceutical | Nitrogenated heterocyclic compound |
| CN104302639B (zh) | 2012-04-25 | 2017-03-29 | 施万生物制药研发Ip有限责任公司 | 作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物 |
| EP2873669A4 (en) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015002230A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | アミド化合物 |
| WO2015002231A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | 複素環化合物 |
| CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
| CN106256819B (zh) * | 2015-06-19 | 2019-07-09 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| WO2016202232A1 (zh) * | 2015-06-19 | 2016-12-22 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| WO2017015439A1 (en) * | 2015-07-21 | 2017-01-26 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a hepatitis c virus inhibitor |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| CN107501155A (zh) * | 2017-09-19 | 2017-12-22 | 上海泓博智源医药股份有限公司 | 一种抗病毒药物中间体的制备方法 |
| CN112679407B (zh) * | 2021-03-17 | 2021-06-04 | 南京桦冠生物技术有限公司 | 一种手性5-取代脯氨酸类化合物的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2299207C2 (ru) * | 2001-08-30 | 2007-05-20 | Кова Ко., Лтд. | Соединения циклического амина |
| US6867221B2 (en) | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
| GB0421908D0 (en) * | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| DE602006016313D1 (de) | 2005-09-16 | 2010-09-30 | Arrow Therapeutics Ltd | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c |
| CN101558059B (zh) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102009005746A1 (de) * | 2009-01-23 | 2010-07-29 | Merck Patent Gmbh | Materialien für organische Elektrolumineszenzvorrichtungen |
| UY32462A (es) * | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2857394A1 (en) | 2009-05-13 | 2015-04-08 | Gilead Pharmasset LLC | Antiviral compounds |
| SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012007420A (es) | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2616461A4 (en) | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POWERFUL AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CN103189371B (zh) * | 2010-11-04 | 2015-04-01 | 施万生物制药研发Ip有限责任公司 | 丙型肝炎病毒抑制剂 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2012
- 2012-11-02 AR ARP120104114A patent/AR088630A1/es unknown
- 2012-11-02 MX MX2014005342A patent/MX347692B/es active IP Right Grant
- 2012-11-02 SG SG11201401891RA patent/SG11201401891RA/en unknown
- 2012-11-02 EP EP12783835.7A patent/EP2773634B1/en active Active
- 2012-11-02 BR BR112014010401A patent/BR112014010401A8/pt not_active IP Right Cessation
- 2012-11-02 RU RU2014122340A patent/RU2625787C2/ru not_active IP Right Cessation
- 2012-11-02 WO PCT/US2012/063181 patent/WO2013067267A1/en active Application Filing
- 2012-11-02 KR KR1020147014928A patent/KR20140091036A/ko not_active Application Discontinuation
- 2012-11-02 CN CN201280054361.3A patent/CN103946220B/zh not_active Expired - Fee Related
- 2012-11-02 AU AU2012332358A patent/AU2012332358B2/en not_active Ceased
- 2012-11-02 TW TW101140863A patent/TWI577672B/zh not_active IP Right Cessation
- 2012-11-02 US US13/667,197 patent/US9212168B2/en not_active Expired - Fee Related
- 2012-11-02 JP JP2014540112A patent/JP6082747B2/ja not_active Expired - Fee Related
- 2012-11-02 CA CA2852700A patent/CA2852700A1/en not_active Abandoned
-
2014
- 2014-04-09 IL IL232042A patent/IL232042A/en not_active IP Right Cessation
- 2014-04-28 CO CO14090226A patent/CO6940424A2/es active IP Right Grant
- 2014-04-29 CL CL2014001110A patent/CL2014001110A1/es unknown
- 2014-05-02 ZA ZA2014/03198A patent/ZA201403198B/en unknown
-
2015
- 2015-02-03 HK HK15101128.6A patent/HK1200812A1/xx unknown
- 2015-10-15 US US14/883,856 patent/US9669027B2/en not_active Expired - Fee Related
-
2016
- 2016-12-06 JP JP2016236386A patent/JP2017048248A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012332358A1 (en) | 2014-05-29 |
| EP2773634A1 (en) | 2014-09-10 |
| IL232042A0 (en) | 2014-05-28 |
| RU2014122340A (ru) | 2015-12-10 |
| CN103946220B (zh) | 2017-12-22 |
| IL232042A (en) | 2017-07-31 |
| NZ623846A (en) | 2016-07-29 |
| JP6082747B2 (ja) | 2017-02-15 |
| MX2014005342A (es) | 2014-08-08 |
| TW201326156A (zh) | 2013-07-01 |
| RU2625787C2 (ru) | 2017-07-19 |
| CN103946220A (zh) | 2014-07-23 |
| ZA201403198B (en) | 2017-04-26 |
| WO2013067267A1 (en) | 2013-05-10 |
| HK1200812A1 (en) | 2015-08-14 |
| BR112014010401A8 (pt) | 2017-12-19 |
| JP2014532716A (ja) | 2014-12-08 |
| MX347692B (es) | 2017-05-09 |
| TWI577672B (zh) | 2017-04-11 |
| SG11201401891RA (en) | 2014-05-29 |
| AU2012332358B2 (en) | 2017-07-13 |
| US9669027B2 (en) | 2017-06-06 |
| EP2773634B1 (en) | 2018-06-06 |
| CL2014001110A1 (es) | 2014-08-22 |
| US9212168B2 (en) | 2015-12-15 |
| BR112014010401A2 (pt) | 2017-04-25 |
| JP2017048248A (ja) | 2017-03-09 |
| CA2852700A1 (en) | 2013-05-10 |
| CO6940424A2 (es) | 2014-05-09 |
| US20160038483A1 (en) | 2016-02-11 |
| US20130115194A1 (en) | 2013-05-09 |
| KR20140091036A (ko) | 2014-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088630A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR110405A1 (es) | Compuestos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
| AR105575A1 (es) | COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR090836A1 (es) | Derivados de benzamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |